AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+11.84%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.89B
AUM Growth
+$3.89B
(+0.38%)
Cap. Flow
-$658M
Cap. Flow
% of AUM
-16.88%
Top 10 Holdings %
Top 10 Hldgs %
78.03%
Holding
129
New
21
Increased
28
Reduced
28
Closed
19
Top Buys
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$96.7M |
| 2 |
Avidity Biosciences
RNA
|
$26.8M |
| 3 |
Cullinan Oncology
CGEM
|
$18.5M |
| 4 |
Merus
MRUS
|
$18.1M |
| 5 |
Vera Therapeutics
VERA
|
$14.8M |
Top Sells
| 1 |
CAVA Group
CAVA
|
$278M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$29.5M |
| 3 |
Viking Therapeutics
VKTX
|
$20.8M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$16.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$14.5M |
Sector Composition
| 1 | Consumer Discretionary | 56.42% |
| 2 | Healthcare | 42.2% |
| 3 | Technology | 0.99% |
| 4 | Financials | 0.15% |
| 5 | Consumer Staples | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Adobe
ADBE
$148B
| $500K | 0.01% |
900
-2,200
| -71% | -$1.22M |
|
102
Intapp
INTA
$3.63B
| $477K | 0.01% |
13,000
-16,500
| -56% | -$605K |
|
103
Tesla
TSLA
$1.08T
| $396K | 0.01% |
2,000
| – | – |
|
104
Remitly
RELY
$4.01B
| $303K | 0.01% |
+25,000
| New | +$303K |
|
105
Cyclerion Therapeutics
CYCN
$7.75M
| $271K | 0.01% |
117,643
-21,312
| -15% | -$49K |
|
106
Caribou Biosciences
CRBU
$176M
| $173K | ﹤0.01% |
105,347
| – | – |
|
107
Dell
DELL
$83.9B
| $138K | ﹤0.01% |
+1,000
| New | +$138K |
|
108
dLocal
DLO
$4.09B
| $84.8K | ﹤0.01% |
10,482
-19,518
| -65% | -$158K |
|
|
PFTAW
109
DELISTED
Perception Capital Corp. III Warrant
PFTAW
| $3.55K | ﹤0.01% |
+126,666
| New | +$3.55K |
|
|
ALPN
110
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-405,784
| Closed | -$16.1M |
|
111
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
112
Vor Biopharma
VOR
$253M
| – | – |
-1,000,000
| Closed | -$2.37M |
|
|
113
Viking Therapeutics
VKTX
$3.02B
| – | – |
-253,863
| Closed | -$20.8M |
|
114
Stoke Therapeutics
STOK
$1.08B
| – | – |
-300,000
| Closed | -$4.05M |
|
115
Repare Therapeutics
RPTX
$73.9M
| – | – |
-700,000
| Closed | -$3.3M |
|
|
116
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
-110,507
| Closed | -$29.5M |
|
117
MiNK Therapeutics
INKT
$63.6M
| – | – |
-1,916
| Closed | -$1.74K |
|
118
Hippo Holdings
HIPO
$810M
| – | – |
-24,000
| Closed | -$438K |
|
119
Structure Therapeutics
GPCR
$1.14B
| – | – |
-151,780
| Closed | -$6.51M |
|
120
Geron
GERN
$893M
| – | – |
-1,281,194
| Closed | -$4.23M |
|
121
Amicus Therapeutics
FOLD
$2.42B
| – | – |
-1,011,776
| Closed | -$11.9M |
|
122
Clearwater Analytics
CWAN
$5.91B
| – | – |
-25,000
| Closed | -$442K |
|
123
Celldex Therapeutics
CLDX
$1.57B
| – | – |
-253,000
| Closed | -$10.6M |
|
124
Axsome Therapeutics
AXSM
$6.09B
| – | – |
-76,837
| Closed | -$6.13M |
|
125
Astria Therapeutics
ATXS
$394M
| – | – |
-884,214
| Closed | -$12.4M |
|